Human clinical studies have shown that GLP-1 receptor agonists may slow down disease progression in those with moderate cognitive impairment (MCI) or early-stage AD and have cognitive benefits (Li et al. 2023a, b). This evidence concerns the gene GLP1R and Alzheimer disease.